The present invention relates to methods, monitors and systems, useful, for example, for advanced detection of sepsis in a subject.

The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value. Further, the invention also provides theragnostics, wherein diagnosis is combined with therapy, more in particular wherein the (plasma) level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that reverse the result of NOX5 activity in the subject, when the determined NOX5 level is exceeding a predetermined threshold level. Finally, the invention relates to an animal model suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension.

The present invention pertains to an enzymatic measurement method using an antibody-enzyme complex or a nucleic acid probe measurement method using an enzyme-labeled nucleic acid probe, in both of which the quantification of a product of a reaction by an enzyme in the antibody-enzyme complex or the enzyme-labeled nucleic acid probe is performed by generating thio-NAD(P)H by an enzymatic cycling reaction using NAD(P)H, thio-NAD(P), and a dehydrogenase (DH), and measuring the amount of the generated thio-NAD(P)H or measuring a change in color caused by the generated thio-NAD(P)H. An enzymatic reaction system in which NAD(P) generated from NAD(P)H by the enzymatic cycling reaction is selectively reduced, is caused to coexist with the enzymatic cycling reaction. The present invention also pertains to a kit for enzyme immunoassay, and a kit for nucleic acid probe measurement. In the enzymatic cycling reaction, the detection sensitivity is increased by increasing the amount of thio-NAD(P)H generated per unit time with respect to a predetermined amount of a substrate (reduced), and combining the same with an enzyme immunoassay, etc., enables quantification, etc., of a protein or nucleic acid with high sensitivity.

The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.

Provided is a ultra-high-sensitivity assay in which the assay can be made on a commonly used assay apparatus such as an absorptiometer and a plate reader or with naked eyes. The high-sensitivity assay in which the assay can be made on a commonly used assay apparatus or with naked eyes can be provided by combining an enzyme cycling method using thio-NAD(P) as a coenzyme, a labeling enzyme and a substrate for the labeling enzyme optimally, and by amplifying thio-NAD(P)H, which is a signaling substance, exponentially and then quantifying the thio-NAD(P)H colorimetrically.

Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.

A method for estimating a number of phagocytes in a body fluid of an animal includes stimulating NADPH oxidase activity of the phagocytes; and quantifying a resulting reductive deoxygenation of a chemiluminigenic substrate by an emitted chemiluminescence of the chemiluminigenic substrate using an instrument capable of measuring light. The NADPH oxidase activity of the phagocytes is preferably stimulated by an immunologic or chemical capable of activating a respiratory burst by the phagocytes, and by a stimulus in solution or coated to a surface contacted by the phagocytes. The stimulus is preferably phorbol myristate acetate (PMA). The animal is preferably human, and the body fluid is preferably blood and/or spinal fluid. The phagocytes are preferably neutrophil leukocytes, and the chemiluminigenic substrate is preferably lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate). Also provided is a method of treatment based on the estimation method.

The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.

The disclosure relates to compositions for use in assays, the compositions comprising at least one latent fluorophore including at least one enzyme-reactive quenching group and a conjugative group; and a support connectable to the latent fluorophore by the conjugative group. The disclosure further relates to methods of measuring the presence and/or concentration of an analyte, as well as methods of measuring the relative activity of at least two enzymes.

The present invention includes a semi-quantitative method for the detection of ENOX2 transcript variants from one or more anti-ENOX2 antibody-binding spots on a blot comprising the steps of: electrophoretically separating proteins from a concentrated blood, serum, or plasma sample from the subject; transferring the electrophoretically separated proteins to a substrate; separating the one or more ENOX2 transcript variants from the one or more anti-ENOX2 antibody-binding spots; and measuring an ENOX2-catalyzed conversion of an ionic silver or gold to a colloidal silver or gold detected by light scattering from the one or more anti-ENOX2 antibody binding spots on the substrate, wherein each of the one or more spots is indicative of the ENOX2 transcript variant. Also provided is the basis for a point of care test to detect ENOX2 transcript variants based on use of colloidal gold or silver complexes with ENOX2 as a rapid simple test for cancer presence.